Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study is aimed to assess the efficacy and safety of Peginterferon alfa-2b (40kD,
Y-shape), in a dose of 180μg/week, in chronic hepatitis B patients, and collects sufficient
evidences for the listed of the studied drug.